We are live on ! Find out more
SRPT icon

Sarepta Therapeutics
SRPT

179 hedge funds and large institutions have $1.21B invested in Sarepta Therapeutics in 2017 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 64 increasing their positions, 44 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

97% more call options, than puts

Call options by funds: $108M | Put options by funds: $54.9M

45% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 44

39% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 28

11% more capital invested

Capital invested by funds: $1.08B → $1.21B (+$123M)

2.09% more ownership

Funds ownership: 72.29% → 74.38% (+2.1%)

1% more funds holding

Funds holding: 177 → 179 (+2)

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

Holders
179
Holders Change
+2
Holders Change %
+1.13%
% of All Funds
4.46%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.05%
New
39
Increased
64
Reduced
44
Closed
28
Calls
$108M
Puts
$54.9M
Net Calls
+$53.5M
Net Calls Change
+$36.4M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$160M
2
HM
HealthCor Management
New York
+$48M
3
CCM
Camber Capital Management
Massachusetts
+$41.8M
4
O
OrbiMed
New York
+$32.6M
5
PC
PointState Capital
New York
+$19.8M

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$62.4M
2
PA
Perceptive Advisors
New York
-$30.9M
3
ACA
Avoro Capital Advisors
New York
-$27.7M
4
JG
Jefferies Group
New York
-$26M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$17.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
Parallax Volatility Advisers
126
Parallax Volatility Advisers
California
$290K +$304K +9,813 New
DCM
127
Dupont Capital Management
Delaware
$286K -$216K -6,995 -42%
FAAS
128
First Allied Advisory Services
California
$285K +$18.6K +600 +7%
Principal Financial Group
129
Principal Financial Group
Iowa
$280K +$3.99K +129 +1%
SGAM
130
Smith Group Asset Management
Texas
$274K – – –
PAM
131
Princeton Alpha Management
New Jersey
$270K +$282K +9,106 New
LP
132
LGL Partners
Pennsylvania
$263K – – –
JGC
133
J. Goldman & Co
New York
$252K -$2.83M -91,400 -91%
AIM
134
Assured Investment Management
New York
$251K +$262K +8,477 New
NPC
135
National Planning Corporation
California
$250K -$173K -5,600 -39%
SFP
136
Shepherd Financial Partners
Massachusetts
$243K – – –
Baird Financial Group
137
Baird Financial Group
Wisconsin
$223K +$234K +7,550 New
BCA
138
Benchmark Capital Advisors
New York
$222K – – –
RJA
139
Raymond James & Associates
Florida
$217K -$88.5K -2,861 -28%
Dimensional Fund Advisors
140
Dimensional Fund Advisors
Texas
$210K +$219K +7,079 New
DTL
141
Dynamic Technology Lab
Singapore
$209K +$218K +7,038 New
LFR
142
Lehman Financial Resources
Pennsylvania
$203K +$212K +6,861 New
FO
143
FT Options
Illinois
$189K -$702K -22,698 -78%
Canada Life
144
Canada Life
Manitoba, Canada
$146K – – –
SG Americas Securities
145
SG Americas Securities
New York
$139K -$903K -29,169 -86%
PNC Financial Services Group
146
PNC Financial Services Group
Pennsylvania
$138K +$86.7K +2,800 +150%
AIP
147
Ameritas Investment Partners
Nebraska
$127K +$133K +4,290 New
CG
148
Cutler Group
California
$114K -$3.41M -110,040 -97%
FAM
149
Fortaleza Asset Management
Illinois
$97K +$63.4K +2,050 +169%
US Bancorp
150
US Bancorp
Minnesota
$68K +$30K +969 +73%
4 5
6
7 8

SRPT Hedge Fund Activity: Q1 2017 in Review

179 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q1 2017, worth a combined $1.21B — up 11% from $1.08B a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new SRPT positions and 28 closed out — a net gain of 11 holders — while 64 added to existing stakes and 44 trimmed.

The largest buyer was BlackRock, adding an estimated $160M. The largest seller was Sabby Management, exiting entirely with an estimated $62.4M sold.

  • 179 institutional investors held Sarepta Therapeutics (SRPT) as of Q1 2017, up from 177 in Q4 2016.
  • Funds reported $1.21B of Sarepta Therapeutics stock for Q1 2017, up 11% quarter-over-quarter.
  • 39 funds opened new Sarepta Therapeutics positions in Q1 2017 and 28 closed out, a net change of +11 holders.
  • The largest Sarepta Therapeutics buyer in Q1 2017 was BlackRock, an estimated $160M added.
  • The largest Sarepta Therapeutics seller in Q1 2017 was Sabby Management, an estimated $62.4M sold.

Based on aggregated 13F filings for Q1 2017.